Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

CD24 expression is a new prognostic marker in breast cancer.

Kristiansen G, Winzer KJ, Mayordomo E, Bellach J, Schlüns K, Denkert C, Dahl E, Pilarsky C, Altevogt P, Guski H, Dietel M.

Clin Cancer Res. 2003 Oct 15;9(13):4906-13.

2.

Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival.

Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P, Dietel M, Kristiansen G.

Clin Cancer Res. 2005 Sep 15;11(18):6574-81.

3.

Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades.

Jacob J, Bellach J, Grützmann R, Alldinger I, Pilarsky C, Dietel M, Kristiansen G.

Pancreatology. 2004;4(5):454-60. Epub 2004 Jul 14.

PMID:
15256807
4.

LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.

Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA.

Anticancer Res. 2004 Jul-Aug;24(4):2391-400.

5.

CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival.

Kristiansen G, Denkert C, Schlüns K, Dahl E, Pilarsky C, Hauptmann S.

Am J Pathol. 2002 Oct;161(4):1215-21.

6.

CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer.

Kristiansen G, Pilarsky C, Pervan J, Stürzebecher B, Stephan C, Jung K, Loening S, Rosenthal A, Dietel M.

Prostate. 2004 Feb 1;58(2):183-92.

PMID:
14716744
7.

CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.

Bircan S, Kapucuoglu N, Baspinar S, Inan G, Candir O.

Pathol Res Pract. 2006;202(8):569-76. Epub 2006 Jul 7.

PMID:
16828238
8.

Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.

Linjawi A, Kontogiannea M, Halwani F, Edwardes M, Meterissian S.

J Am Coll Surg. 2004 Jan;198(1):83-90.

PMID:
14698315
9.

CD24 expression has a prognostic impact in breast carcinoma.

Athanassiadou P, Grapsa D, Gonidi M, Athanassiadou AM, Tsipis A, Patsouris E.

Pathol Res Pract. 2009;205(8):524-33. doi: 10.1016/j.prp.2009.01.008. Epub 2009 Feb 24.

PMID:
19243896
10.

Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis.

Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H.

Clin Cancer Res. 2005 Feb 1;11(3):1154-9.

11.

Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.

Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM.

Clin Cancer Res. 2004 Nov 15;10(22):7621-8.

12.

Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors.

Choi YL, Kim SH, Shin YK, Hong YC, Lee SJ, Kang SY, Ahn G.

Gynecol Oncol. 2005 May;97(2):379-86.

PMID:
15863133
13.

Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer.

Neri A, Marrelli D, Pedrazzani C, Caruso S, De Stefano A, Mariani F, Megha T, De Marco G, Corso G, Pinto E, Roviello F.

Eur J Surg Oncol. 2008 Dec;34(12):1299-303. doi: 10.1016/j.ejso.2007.11.009. Epub 2008 Mar 4.

PMID:
18164172
14.

CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients.

Kristiansen G, Schlüns K, Yongwei Y, Denkert C, Dietel M, Petersen I.

Br J Cancer. 2003 Jan 27;88(2):231-6.

15.

The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells.

Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Lopez-Bonet E, Menendez JA.

Oncol Rep. 2011 Jan;25(1):135-40.

PMID:
21109968
16.

Nuclear localization of KLF4 is associated with an aggressive phenotype in early-stage breast cancer.

Pandya AY, Talley LI, Frost AR, Fitzgerald TJ, Trivedi V, Chakravarthy M, Chhieng DC, Grizzle WE, Engler JA, Krontiras H, Bland KI, LoBuglio AF, Lobo-Ruppert SM, Ruppert JM.

Clin Cancer Res. 2004 Apr 15;10(8):2709-19.

17.

CD24 expression is specific for tamoxifen-resistant ductal breast cancer cases.

Surowiak P, Materna V, Paluchowski P, Matkowski R, Wojnar A, Maciejczyk A, Pudelko M, Kornafel J, Dietel M, Kristiansen G, Lage H, Zabel M.

Anticancer Res. 2006 Jan-Feb;26(1B):629-34.

18.

Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer.

Mell LK, Meyer JJ, Tretiakova M, Khramtsov A, Gong C, Yamada SD, Montag AG, Mundt AJ.

Clin Cancer Res. 2004 Aug 15;10(16):5546-53.

19.

CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma.

Sano A, Kato H, Sakurai S, Sakai M, Tanaka N, Inose T, Saito K, Sohda M, Nakajima M, Nakajima T, Kuwano H.

Ann Surg Oncol. 2009 Feb;16(2):506-14. doi: 10.1245/s10434-008-0252-0. Epub 2008 Dec 3.

PMID:
19050962
20.

Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer.

Burkhardt M, Mayordomo E, Winzer KJ, Fritzsche F, Gansukh T, Pahl S, Weichert W, Denkert C, Guski H, Dietel M, Kristiansen G.

J Clin Pathol. 2006 Apr;59(4):403-9. Epub 2006 Feb 16.

Supplemental Content

Support Center